Oncternal Therapeutics (NASDAQ:ONCT) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
Profitability
This table compares Oncternal Therapeutics and uniQure's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Oncternal Therapeutics | -746.10% | -150.58% | -91.87% |
| uniQure | -2,738.33% | -59.64% | -41.47% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Oncternal Therapeutics and uniQure, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Oncternal Therapeutics | 0 | 0 | 5 | 0 | 3.00 |
| uniQure | 0 | 1 | 11 | 1 | 3.00 |
Oncternal Therapeutics currently has a consensus price target of $15.20, indicating a potential upside of 84.02%. uniQure has a consensus price target of $68.4615, indicating a potential upside of 102.91%. Given uniQure's higher probable upside, analysts clearly believe uniQure is more favorable than Oncternal Therapeutics.
Earnings and Valuation
This table compares Oncternal Therapeutics and uniQure's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Oncternal Therapeutics | $2.42 million | 168.49 | $-34,190,000.00 | ($1.56) | -5.29 |
| uniQure | $7.28 million | 208.53 | $-124,200,000.00 | ($3.11) | -10.85 |
Oncternal Therapeutics has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
10.8% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 78.3% of uniQure shares are held by institutional investors. 10.9% of Oncternal Therapeutics shares are held by insiders. Comparatively, 2.8% of uniQure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Oncternal Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, uniQure has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
Summary
uniQure beats Oncternal Therapeutics on 8 of the 14 factors compared between the two stocks.
